Catalogue
Every compound. Independently verified.
Five categories, one standard. Batches are verified in our Canadian lab before they list — tested locally, before orders are shipped.
GHK-Cu drives extracellular matrix biology and tissue remodelling. Combined with BPC-157 and TB-500, GLOW addresses three complementary longevity pathways in a single, Canadian-lab verified vial.
Recovery
4 compounds. Same standard.
Body Protection Compound. Researched for tissue repair signalling across muscle, tendon, ligament, and gastrointestinal systems.
Combines localized tissue repair (BPC-157) with systemic cellular migration (TB-500). Two complementary recovery pathways in a single lyophilized vial.
Synthetic Thymosin Beta-4 analogue. Researched for systemic cellular migration, reduced scar formation, and fibrosis modulation.
Alpha-MSH derived tripeptide. Researched for potent anti-inflammatory activity via NF-κB pathway modulation.
Strength
3 compounds. Same standard.
Selective GHS-R1a agonist. Researched for pulsatile GH release with minimal off-target endocrine activity.
Synthetic GHRH analogue. Investigated for GH axis stimulation and body composition modulation.
GHRH analogue paired with a selective GH secretagogue. CJC-1295 amplifies pulse amplitude; Ipamorelin increases pulse frequency — two complementary inputs on the growth hormone axis in a single vial.
Longevity
4 compounds. Same standard.
Copper-binding tripeptide. Researched for extracellular matrix remodelling, collagen synthesis, and tissue repair signalling.
Tetrapeptide studied for telomerase activation and pineal gland bioregulation in aging research models.
Mitochondrial-derived peptide. Investigated for metabolic homeostasis, exercise mimetic effects, and cellular energy regulation.
Mitochondria-targeted peptide (Elamipretide). Researched for cardiolipin stabilization and mitochondrial electron transport chain protection.
Weight Loss
One compound. Definitive scope.
Ancillaries